Jan 30, 2018 • 7:05 am EST Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of Lenabasum
Jan 29, 2018 • 4:05 pm EST Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint